Comparison between screen-detected and symptomatic breast cancers according to molecular subtypes

Abstract

Breast cancer screening programs make it possible to detect early cancer, thus reducing breast cancer mortality. We studied the clinicopathologic characteristics and prognosis of screen-detected invasive breast cancer compared with symptomatic breast cancer. And we compared the result according to molecular subtypes (luminal A, luminal B, Her2, and triple negative), with the goal of identifying the role of screening in each subtypes. From January 2002 to June 2008, 3,141 patients who underwent surgery for the treatment of invasive ductal carcinoma at Samsung Medical Center were included. Among them, 1,025 patients were screen-detected, and 2,116 patients who were screened over 2 years or never were symptomatic. We retrospectively reviewed the clinical and pathologic data. Screen-detected breast cancer was associated with older age, smaller tumor size, more hormone-receptor positive, less lymph node involvement, earlier stage, and reduced mortality compared with symptomatic breast cancer (P < 0.001). According to the molecular subtype, luminal A was most common (63.6%) and showed the most obvious survival benefit in screen-detected tumors in comparison with symptomatic tumors (5-year OS: 99.7 vs. 96.5%, 5-year DFS: 96.4 vs. 90.7%). Screen detection was independently associated with improved overall and disease-free survival outcomes after adjustment for covariates (HR 0.32, P = 0.035; HR 0.58, P = 0.020, respectively) only in the luminal A subtype. Differences in pathological features such as tumor size, nodal status, grade, and age at diagnosis with different molecular subtype distributions may explain the survival advantage of patients with screen-detected breast cancer. Screening programs seem to have a different efficacy depending on the molecular subtype of the breast cancer, especially in the luminal A subtype, for which screen detection acts as an independent prognostic factor itself.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

References

  1. 1.

    Joensuu H, Lehtimaki T, Holli K, Elomaa L, Turpeenniemi-Hujanen T, Kataja V, Anttila A, Lundin M, Isola J, Lundin J (2004) Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA 292:1064–1073

    PubMed  Article  CAS  Google Scholar 

  2. 2.

    Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA (2005) Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 97:1195–1203

    PubMed  Article  Google Scholar 

  3. 3.

    Kalager M, Haldorsen T, Bretthauer M, Hoff G, Thoresen SO, Adami HO (2009) Improved breast cancer survival following introduction of an organized mammography screening program among both screened and unscreened women: a population-based cohort study. Breast Cancer Res 11:R44

    PubMed  Article  Google Scholar 

  4. 4.

    Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. Engl J Med 353:1784–1792

    Article  CAS  Google Scholar 

  5. 5.

    Mook S, Van ‘t Veer LJ, Rutgers EJ, Ravdin PM, van de Velde AO, van Leeuwen FE, Visser O, Schmidt MK (2011) Independent prognostic value of screen detection in invasive breast cancer. J Natl Cancer Inst 103:585–597

    PubMed  Article  Google Scholar 

  6. 6.

    Dawson SJ, Duffy SW, Blows FM, Driver KE, Provenzano E, LeQuesne J, Greenberg DC, Pharoah P, Caldas C, Wishart GC (2009) Molecular characteristics of screen-detected vs. symptomatic breast cancers and their impact on survival. Br J Cancer 101:1338–1344

    PubMed  Article  CAS  Google Scholar 

  7. 7.

    Sihto H, Lundin J, Lehtimaki T, Sarlomo-Rikala M, Butzow R, Holli K, Sailas L, Kataja V, Lundin M, Turpeenniemi-Hujanen T, Isola J, Heikkila P, Joensuu H (2008) Molecular subtypes of breast cancers detected in mammography screening and outside of screening. Clin Cancer Res 14:4103–4110

    PubMed  Article  CAS  Google Scholar 

  8. 8.

    Nagtegaal ID, Allgood PC, Duffy SW, Kearins O, Sullivan EO, Tappenden N, Wallis M, Lawrence G (2011) Prognosis and pathology of screen-detected carcinomas: how different are they? Cancer 117:1360–1368

    PubMed  Article  Google Scholar 

  9. 9.

    Weaver DL, Rosenberg RD, Barlow WE, Ichikawa L, Carney PA, Kerlikowske K, Buist DS, Geller BM, Key CR, Maygarden SJ, Ballard-Barbash R (2006) Pathologic findings from the Breast Cancer Surveillance Consortium: population-based outcomes in women undergoing biopsy after screening mammography. Cancer 106:732–742

    PubMed  Article  Google Scholar 

  10. 10.

    Ernst MF, Roukema JA, Coebergh JW, Repelaer van Driel OJ, van Beek MW, van der Sangen MJ, Voogd AC (2002) Breast cancers found by screening: earlier detection, lower malignant potential or both? Breast Cancer Res Treat 76:19–25

    PubMed  Article  CAS  Google Scholar 

  11. 11.

    Allgood PC, Duffy SW, Kearins O, O’Sullivan E, Tappenden N, Wallis MG, Lawrence G (2011) Explaining the difference in prognosis between screen-detected and symptomatic breast cancers. Br J Cancer 104:1680–1685

    PubMed  Article  CAS  Google Scholar 

  12. 12.

    Hutchison GB, Shapiro S (1968) Lead time gained by diagnostic screening for breast cancer. J Natl Cancer Inst 41:665–681

    PubMed  CAS  Google Scholar 

  13. 13.

    Shapiro S, Goldberg JD, Hutchison GB (1974) Lead time in breast cancer detection and implications for periodicity of screening. Am J Epidemiol 100:357–366

    PubMed  CAS  Google Scholar 

  14. 14.

    Zahl PH, Strand BH, Maehlen J (2004) Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. BMJ 328:921–924

    PubMed  Article  Google Scholar 

  15. 15.

    Wishart GC, Greenberg DC, Britton PD, Chou P, Brown CH, Purushotham AD, Duffy SW (2008) Screen-detected vs. symptomatic breast cancer: is improved survival due to stage migration alone? Br J Cancer 98:1741–1744

    PubMed  Article  CAS  Google Scholar 

  16. 16.

    Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100:10393–10398

    PubMed  Article  CAS  Google Scholar 

  17. 17.

    Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL, Harris JR (2008) Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26:2373–2378

    PubMed  Article  Google Scholar 

  18. 18.

    Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418–8423

    PubMed  Article  CAS  Google Scholar 

  19. 19.

    Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874

    PubMed  Article  CAS  Google Scholar 

  20. 20.

    Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406:747–752

    PubMed  Article  CAS  Google Scholar 

  21. 21.

    Jacquemier J, Ginestier C, Rougemont J, Bardou VJ, Charafe-Jauffret E, Geneix J, Adelaide J, Koki A, Houvenaeghel G, Hassoun J, Maraninchi D, Viens P, Birnbaum D, Bertucci F (2005) Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 65:767–779

    PubMed  CAS  Google Scholar 

  22. 22.

    Makretsov NA, Huntsman DG, Nielsen TO, Yorida E, Peacock M, Cheang MC, Dunn SE, Hayes M, van de Rijn M, Bajdik C, Gilks CB (2004) Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. Clin Cancer Res 10:6143–6151

    PubMed  Article  CAS  Google Scholar 

  23. 23.

    Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC cancer staging manual, 7th edn. Springer, New York

    Google Scholar 

  24. 24.

    Bloom HJ, Richardson WW (1957) Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11:359–377

    PubMed  Article  CAS  Google Scholar 

  25. 25.

    Colozza M, Sidoni A, Piccart-Gebhart M (2010) Value of Ki67 in breast cancer: the debate is still open. Lancet Oncol 11:414–415

    PubMed  Article  Google Scholar 

  26. 26.

    Jung KW, Park S, Kong HJ, Won YJ, Lee JY, Park EC, Lee JS (2011) Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008. Cancer Res Treat 43:1–11

    PubMed  Article  Google Scholar 

  27. 27.

    Korean Breast Cancer Society (2008) 2006–2008 Breast cancer facts & figures. Korean Breast Cancer Society, Seoul

  28. 28.

    Lim SM, Lee HY, Choi KS, Jun JK, Park EC, Kim Y, Han MA, Oh DK, Shim JI (2010) Trends of mammography use in a national breast cancer screening program, 2004–2008. Cancer Res Treat 42:199–202

    PubMed  Article  Google Scholar 

  29. 29.

    Oh DK, Shim JI, Han M, Kim Y, Lee HY, Jun JK, Choi KS, Park EC (2010) Breast cancer screening in Korean women: report of the national cancer screening program in 2008. J Breast Cancer 13:299–304

    Article  Google Scholar 

  30. 30.

    Bastos J, Peleteiro B, Gouveia J, Coleman MP, Lunet N (2010) The state of the art of cancer control in 30 European countries in 2008. Int J Cancer 126:2700–2715

    PubMed  CAS  Google Scholar 

  31. 31.

    Anderson TJ, Lamb J, Donnan P, Alexander FE, Huggins A, Muir BB, Kirkpatrick AE, Chetty U, Hepburn W, Smith A et al (1991) Comparative pathology of breast cancer in a randomised trial of screening. Br J Cancer 64:108–113

    PubMed  Article  CAS  Google Scholar 

  32. 32.

    Lindgren A, Holmberg L, Thurfjell E (1997) The influence of mammography screening on the pathological panorama of breast cancer. APMIS 105:62–70

    PubMed  Article  CAS  Google Scholar 

  33. 33.

    de Roos MA, van der Vegt B, de Vries J, Wesseling J, de Bock GH (2007) Pathological and biological differences between screen-detected and interval ductal carcinoma in situ of the breast. Ann Surg Oncol 14:2097–2104

    PubMed  Article  Google Scholar 

  34. 34.

    Cowan WK, Kelly P, Sawan A, Cunliffe WJ, Henry L, Higgs MJ, Lunt LG, Young JR, Horne CH, Angus B (1997) The pathological and biological nature of screen-detected breast carcinomas: a morphological and immunohistochemical study. J Pathol 182:29–35

    PubMed  Article  CAS  Google Scholar 

  35. 35.

    Chu KC, Smart CR, Tarone RE (1988) Analysis of breast cancer mortality and stage distribution by age for the Health Insurance Plan clinical trial. J Natl Cancer Inst 80:1125–1132

    PubMed  Article  CAS  Google Scholar 

  36. 36.

    Cowan WK, Angus B, Henry J, Corbett IP, Reid WA, Horne CH (1991) Immunohistochemical and other features of breast carcinomas presenting clinically compared with those detected by cancer screening. Br J Cancer 64:780–784

    PubMed  Article  CAS  Google Scholar 

  37. 37.

    Paci E, Ponti A, Zappa M, Patriarca S, Falini P, Delmastro G, Bianchi S, Sapino A, Vezzosi V, Senore C, Crocetti E, Frigerio A, Zanetti R, Del Turco MR, Segnan N (2005) Early diagnosis, not differential treatment, explains better survival in service screening. Eur J Cancer 41:2728–2734

    PubMed  Article  Google Scholar 

  38. 38.

    Biesheuvel C, Czene K, Orgeas CC, Hall P (2011) The role of mammography screening attendance and detection mode in predicting breast cancer survival-Is there added prognostic value? Cancer Epidemiol (in press). doi:10.1016/j.canep.2011.02.008

  39. 39.

    Gill PG (2004) Detection by screening mammography is a powerful independent predictor of survival in women diagnosed with breast cancer. Breast 13:15–22

    PubMed  Article  CAS  Google Scholar 

  40. 40.

    Todd JH, Dowle C, Williams MR, Elston CW, Ellis IO, Hinton CP, Blamey RW, Haybittle JL (1987) Confirmation of a prognostic index in primary breast cancer. Br J Cancer 56:489–492

    PubMed  Article  CAS  Google Scholar 

  41. 41.

    Miles A, Cockburn J, Smith RA, Wardle J (2004) A perspective from countries using organized screening programs. Cancer 101:1201–1213

    PubMed  Article  Google Scholar 

Download references

Acknowledgments

This study was supported by a grant of the Korea Healthcare Technology R&D Project, Ministry for Health & Welfare Affairs, Republic of Korea (A092255).

Author information

Affiliations

Authors

Corresponding author

Correspondence to Jeong Eon Lee.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kim, J., Lee, S., Bae, S. et al. Comparison between screen-detected and symptomatic breast cancers according to molecular subtypes. Breast Cancer Res Treat 131, 527–540 (2012). https://doi.org/10.1007/s10549-011-1836-0

Download citation

Keywords

  • Breast cancer
  • Screen-detected
  • Molecular subtype
  • Prognosis